DehydraTECH-Nicotine
Smoking Cessation
Key Facts
About Lexaria Bioscience
Lexaria Bioscience is a micro-cap biotech focused on commercializing its proprietary DehydraTECH™ drug delivery platform. The company's mission is to improve the performance of existing and new oral pharmaceuticals, particularly fat-soluble molecules, by increasing their bioavailability and onset speed. Its strategy is purely licensing-based, partnering with established pharmaceutical and consumer product companies to integrate DehydraTECH into their pipelines. Key achievements include a robust global patent portfolio, positive human clinical data across multiple drug classes, and a lean operational structure that extends its capital runway.
View full company profileTherapeutic Areas
Other Smoking Cessation Drugs
| Drug | Company | Phase |
|---|---|---|
| Nicotine Oral Strip | CTT Pharma | Pre-clinical |
| Smoking Cessation Program | Qnovia | Pre-clinical |
| Platform Expansion | Amygdala Neurosciences | Research |
| NFL-101 | NFL Biosciences | Phase 2 |
| NFL-102 | NFL Biosciences | Phase 2 |
| Varenicline Tablets | Indoco Remedies | Approved |